Three step high-dose chemotherapy in poor prognosis non-Hodgkin lymphoma.

被引：0
|
作者：
Ballestrero, A
Clavio, M
Ferrando, F
Secondo, V
Basta, P
Gonella, R
Garuti, A
Miglino, M
Pierri, I
Canepa, L
Beltrami, G
Vallebella, E
Ghio, R
Gobbi, M
Patrone, F
机构：
[1] Univ Genova, Sez Oncol & Ematol DIML, Genoa, Italy
[2] OC Galliera, Div Med, Genova, Italy
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
613
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [31] High cyclophosphamide dose (CTX) in CHOP regimen is safe for aggressive non-Hodgkin lymphoma.
    Dann, EJ
    Drumea, K
    Haddad, N
    Hoffman, R
    Rosenbaum, H
    Zuckerman, T
    Ben-Shachar, M
    Haim, N
    Epelbaum, R
    Rowe, JM
    BLOOD, 2000, 96 (11) : 235B - 235B
  • [32] Results of high dose chemotherapy and autologous stem cell transplantation in patients with high and low grade non-Hodgkin's lymphoma.
    Ault, KA
    Case, DC
    Boyd, MA
    Ervin, TJ
    Aronson, FR
    Ebrahim, KS
    Hedlund, JA
    BLOOD, 2001, 98 (11) : 389B - 389B
  • [33] Impact of absolute lymphocyte count on prognosis of aggressive non-Hodgkin lymphoma.
    Kaur, Anahat
    Grover, Punita
    Bulchandani, Sheetal
    Odeny, Thomas A.
    Madhusudhana, Sheshadri
    Shrestha, Anuj
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] High-dose chemotherapy in children and adolescents with poor-prognosis Hodgkin's disease
    Kabickova, E
    Sumerauer, D
    Kobylka, P
    Cumlivska, E
    Vicha, A
    Valkova, J
    Kodet, R
    Koutecky, J
    BONE MARROW TRANSPLANTATION, 2003, 31 : S243 - S244
  • [35] Intensified, sort duration chemotherapy of pediatric non-Hodgkin's lymphoma.
    Mukhopadhyay, A
    Saha, K
    Kundu, B
    Barman, B
    Sarkar, R
    Jana, S
    Gupta, PR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 815S - 815S
  • [36] Effect of follicularity on outcome of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) for large cell non-Hodgkin's lymphoma.
    Vose, J
    Lynch, J
    Bierman, P
    Anderson, J
    Kessinger, A
    Armitage, JO
    BLOOD, 1996, 88 (10) : 476 - 476
  • [37] Comparison of the sequential high-dose chemotherapy followed by autologous stem cell support with and without rituximab in relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Sieniawski, M
    Staak, JO
    Scheuss, H
    Glossmann, JP
    Diehl, V
    Engert, A
    Josting, A
    BLOOD, 2004, 104 (11) : 263A - 263A
  • [38] BEAM vs BuMeITT high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell infusion (HSCT) in the treatment of non-Hodgkin's lymphoma.
    Zaucha, R
    Holmberg, L
    Maloney, D
    Press, O
    Bensinger, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 604S - 604S
  • [39] Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft
    Tarella, C
    Caracciolo, D
    Gavarotti, P
    Argentino, C
    Zallio, F
    Corradini, P
    Novero, D
    Magnani, C
    Pileri, A
    BONE MARROW TRANSPLANTATION, 2000, 26 (11) : 1185 - 1191
  • [40] High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma
    Ballestrero, A
    Clavio, M
    Ferrando, F
    Gonella, R
    Garuti, A
    Sessarego, M
    Ghio, R
    Gobbi, M
    Patrone, F
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2000, 17 (05) : 1007 - 1013
12345